Want to see CH:MEDX full AI Analyst Report?
MEDX Stock Chart & Stats
CHF9.12
CHF0.32(2.96%)
At close: 4:00 PM EST
CHF9.12
CHF0.32(2.96%)
Day’s Range― - ―
52-Week RangeCHF7.72 - CHF13.02
Previous CloseN/A
Volume22.50K
Average Volume (3M)115.75K
Market Cap
CHF330.10M
Enterprise ValueCHF567.67M
Total Cash (Recent Filing)CHF113.90M
Total Debt (Recent Filing)CHF330.30M
Price to Earnings (P/E)49.9
Beta1.04
Next Earnings
Jul 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield4.54%
Share Statistics
EPS (TTM)0.16
Shares Outstanding41,262,370
10 Day Avg. Volume183,978
30 Day Avg. Volume115,752
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)1.08
Price to Sales (P/S)1.02
P/FCF Ratio13.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.5
Revenue Forecast (FY)CHF448.65M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables & OEM Relationshipsmedmix’s business mixes one-time equipment sales with recurring consumables and long OEM supply relationships. That revenue mix creates stickiness and predictable repeat demand, supporting durable revenue streams and higher lifetime customer value versus pure equipment suppliers.
Positive Free Cash Flow GenerationDespite volatility, medmix generated positive free cash flow in 2025, giving it the ability to fund operations, capital needs and service debt without relying solely on external financing. Persistent FCF, even if variable, underpins financial flexibility over coming quarters.
Specialized, Diversified End-marketsmedmix’s engineered, high-precision products serve multiple end-markets—notably regulated healthcare—where qualification and precision create higher barriers to entry. Diversified end-market exposure reduces single-industry cyclicality and supports steadier structural demand.
Bears Say
Top-line Softness And Recent Revenue DeclineRevenue has stagnated and slipped recently, reflecting softer demand or market share pressure. A declining top line limits the firm’s ability to leverage fixed costs, constrains reinvestment capacity, and makes margin recovery and return improvements harder to sustain.
Thin Margins And Very Low Returns On EquityNet margins near 1% and ROE around 1.5% indicate weak profitability relative to capital employed. Persistently thin margins reduce free cash generation per sales and limit capacity to build reserves or fund growth without materially improving operating efficiency or pricing.
Higher Leverage And Volatile Cash ConversionDebt near parity with equity reduces financial flexibility versus a lower-leverage profile, while a sharp FCF drop shows cash conversion can swing materially. Combined, higher leverage plus FCF volatility raises refinancing and investment risk in adverse cycles.
medmix AG News
MEDX FAQ
What was medmix AG’s price range in the past 12 months?
medmix AG lowest stock price was CHF7.72 and its highest was CHF13.02 in the past 12 months.
What is medmix AG’s market cap?
medmix AG’s market cap is CHF330.10M.
When is medmix AG’s upcoming earnings report date?
medmix AG’s upcoming earnings report date is Jul 23, 2026 which is in 21 days.
How were medmix AG’s earnings last quarter?
medmix AG released its earnings results on Feb 26, 2026. The company reported CHF0.33 earnings per share for the quarter, the consensus estimate of CHF0.33 by CHF0.
Is medmix AG overvalued?
According to Wall Street analysts medmix AG’s price is currently Overvalued.
Does medmix AG pay dividends?
medmix AG pays a Annually dividend of CHF0.1 which represents an annual dividend yield of 4.54%. See more information on medmix AG dividends here
What is medmix AG’s EPS estimate?
medmix AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does medmix AG have?
medmix AG has 41,262,370 shares outstanding.
What happened to medmix AG’s price movement after its last earnings report?
medmix AG reported an EPS of CHF0.33 in its last earnings report, expectations of CHF0.33. Following the earnings report the stock price went down -14.856%.
Which hedge fund is a major shareholder of medmix AG?
Currently, no hedge funds are holding shares in CH:MEDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
medmix AG
Established in 1922 and headquartered in Zug, Switzerland, Medmix AG stands as a global leader in innovating, manufacturing, and distributing high-precision devices and services. These solutions are meticulously engineered for the controlled mixing, application, and injection of liquids across various viscosities, serving diverse healthcare, consumer, and industrial markets worldwide. The company operates through five key divisions: Dental, Drug Delivery, Surgery, Industry, and Beauty. The Dental segment offers essential tools such as mixing tips, dispensers, needles, and accessories, alongside support services for applications including prosthetics, restorative procedures, anesthesiology, and cosmetic dentistry. In its Drug Delivery segment, Medmix develops critical devices for administering medications like fertility drugs, growth hormones, and treatments for specific diabetes conditions, osteoporosis, and rare diseases. The Surgery segment provides specialized mixing and delivery systems utilized for injecting bone cement and applying hemostatic sealants to manage both internal and external wounds during surgical interventions. For industrial clients, the Industry division produces robust dispensers, cartridges, and mixers for two-component adhesives and sealants, indispensable in sectors such as construction, transportation, electronics, infrastructure, and broader manufacturing. Lastly, the Beauty segment supplies micro brushes, mascara applicators, lip gloss, and concealers. Medmix AG markets its comprehensive product range under well-recognized brands, including Mixpac, Transcodent, Cox, MK, Medmix, Haselmeier, and Geka.
Technical Analysis
Rieter Holding AG
―
Komax Holding AG
―
―
Mikron Holding AG
―
StarragTornos Group AG
―
Options Prices
Currently, No data available
---





